Real-World Outcomes of PRESERFLO MicroShunt Implantations With and Without Adjunctive Healaflow® Application in Glaucoma Patients: A Single-Center Experience.

Authors

Dominique Frédéric Waldmann, Konstantin Gugleta, Thomas Dervos, Tim J Enz, Oussama Habra

Published in

Klinische Monatsblatter fur Augenheilkunde. Oct 09, 2026. Epub Oct 09, 2026.

Abstract

INTRODUCTION: This report describes our experience with PRESERFLO MicroShunt implantation with and without adjunctive subconjunctival Healaflow® as a modified bleb-forming filtration technique in glaucoma patients.
MATERIALS AND METHODS: A retrospective cohort analysis of 65 consecutive eyes undergoing single PRESERFLO MicroShunt implantation at a single center was performed. The Healaflow group (HG; n = 36, with Healaflow®) was operated between October 2024 and July 2025, and the control group (CG; n = 29, without Healaflow®) between October 2018 and December 2019. Medical records were reviewed for demographics, intraocular pressure (IOP), medication use and complications. IOP and topical medication were compared between groups preoperatively, on day 1, week 1, and at 1-3, 3-6, 6-12 and 12-18 months using unpaired t-tests and a two-way repeated-measures ANOVA.
RESULTS: Mean preoperative IOP was comparable between groups (24.4 ± 9.4 vs. 21.8 ± 8.2 mmHg; p = 0.24). IOP was significantly lower in the HG at 1-3 months (8.6 ± 4.0 vs. 14.0 ± 9.2; p = 0.007), 3-6 months (10.4 ± 5.4 vs. 14.9 ± 7.1; p = 0.031) and 6-12 months (11.0 ± 4.0 vs. 15.4 ± 5.3; p = 0.004), and remained nominally lower at 12-18 months (11.6 ± 6.0 vs. 13.8 ± 5.3; p = 0.254). The ANOVA showed a significant group-by-time interaction (p = 0.001) in favour of the HG. Topical medication was consistently lower in the HG (6-12 months: 0.41 vs. 1.38 compounds). Transient, self-limiting hypotony-related choroidal detachment/effusion occurred in 27.8% (HG) vs. 13.8% (CG); bleb revision was required in 8.3% vs. 13.8%.
DISCUSSION/CONCLUSION: PRESERFLO MicroShunt implantation with adjunctive subconjunctival Healaflow® may provide a greater and more sustained IOP reduction and a lower medication burden than MicroShunt with mitomycin C alone, at least in the early-to-mid postoperative period and in the absence of postoperative 5-fluorouracil. Transient hypotony was more frequent but reversible. Further, prospective and standardized comparisons are warranted.

PMID:
42854739
Bibliographic data and abstract were imported from PubMed on 10 Oct 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.